Regency Capital Management Inc. DE Has $3.17 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Regency Capital Management Inc. reduced its holdings in Thermo Fisher Scientific Inc. by 21.5%, owning 7,829 shares valued at approximately $3.17 million, making it the firm’s 22nd largest investment.
• Thermo Fisher Scientific recently reported a Q2 earnings per share (EPS) of $5.36, beating estimates, and provided an EPS guidance of $5.460-5.510 for Q3 2025.
• The company also declared a quarterly dividend of $0.43 per share, which will be paid on October 15th, reflecting a yield of 0.3%.

Regency Capital Management Inc. DE reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 7,829 shares of the medical research company's stock after selling 2,145 shares during the period. Thermo Fisher Scientific accounts for approximately 1.7% of Regency Capital Management Inc. DE's investment portfolio, making the stock its 22nd largest holding. Regency Capital Management Inc. DE's holdings in Thermo Fisher Scientific were worth $3,174,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in TMO. Nuveen LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth $532,360,000. Sarasin & Partners LLP bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $187,134,000. EdgePoint Investment Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $172,139,000. Cohen Investment Advisors LLC grew its holdings in Thermo Fisher Scientific by 6,655.5% during the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after purchasing an additional 331,180 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TMO. HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Barclays raised their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a report on Thursday. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $585.37.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $544.44 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business has a 50-day moving average of $483.77 and a 200-day moving average of $446.95. The stock has a market capitalization of $205.59 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.